CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation

Sci Adv. 2020 May 20;6(21):eaba2983. doi: 10.1126/sciadv.aba2983. eCollection 2020 May.

Abstract

CRISPR-Cas12a represents an efficient tool for genome editing in addition to the extensively investigated CRISPR-Cas9. However, development of efficient nonviral delivery system for CRISPR-Cas12a remains challenging. Here, we demonstrate a DNA nanoclew (NC)-based carrier for delivery of Cas12a/CRISPR RNA (crRNA) ribonucleoprotein (RNP) toward regulating serum cholesterol levels. The DNA NC could efficiently load the Cas12a/crRNA RNP through complementation between the DNA NC and the crRNA. Addition of a cationic polymer layer condensed the DNA-templated core and allowed further coating of a charge reversal polymer layer, which makes the assembly negatively charged under a physiological pH but reverts to positive charge under an acidic environment. When Pcsk9 was selected as the target gene because of its important role in regulating the level of serum cholesterol, efficient Pcsk9 disruption was observed in vivo (~48%), significantly reducing the expression of PCSK9 and gaining the therapeutic benefit of cholesterol control (~45% of cholesterol reduction).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems*
  • Cholesterol
  • DNA / genetics
  • DNA / metabolism
  • Gene Editing
  • Polymers / metabolism
  • Proprotein Convertase 9* / genetics
  • Proprotein Convertase 9* / metabolism
  • RNA / genetics
  • Ribonucleoproteins / genetics

Substances

  • Polymers
  • Ribonucleoproteins
  • RNA
  • DNA
  • Cholesterol
  • PCSK9 protein, human
  • Proprotein Convertase 9